Drug intelligence / Profile preview

LY4066708

Development stage: Phase 1
Lead developer: Eli Lilly
Administration: Intravenous, Subcutaneous

Overview

LY4066708 is an investigational drug currently in early-stage clinical trials for safety, tolerability, and pharmacokinetic profiling in healthy volunteers. It is being developed as a potential therapeutic; however, the specific mechanism of action, molecular target, indications, and chemical modality have not been publicly disclosed in available clinical trial summaries as of July 2025. The ongoing studies are single- and multiple-ascending dose trials assessing safety and side effects in healthy populations[1][3][4][7][8].

Beyond the preview

Go deeper on LY4066708.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4066708.

Explore the full profile